Enliven Therapeutics ELVN Gain/Loss on Asset Sales
Gain/Loss on Asset Sales at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets.
The official record: Enliven Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's gain/loss on asset sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's gain/loss on asset sales?
- Enliven Therapeutics (ELVN) reported gain/loss on asset sales of -$26.5K in Q4 2025.
- How has Enliven Therapeutics's gain/loss on asset sales changed year-over-year?
- Enliven Therapeutics's gain/loss on asset sales decreased by 863.6% year-over-year, from -$2.75K to -$26.5K.
- What is the long-term trend for Enliven Therapeutics's gain/loss on asset sales?
- Over 2 years (2022 to 2025), Enliven Therapeutics's gain/loss on asset sales has grown at a -94.5% compound annual growth rate (CAGR), from $35M to -$106K.
- What does gain/loss on asset sales mean?
- Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.